ArticleACS omega2026
Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer Cells and Organotypic Tumor Slice Culture.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Forkhead box M1 (FOXM1) transcription factor, recognized as a prominent oncogene, facilitates cell cycle progression and mitotic fidelity in aggressive cancers. Overexpression of FOXM1 is correlated with uncontrolled cell proliferation, metastasis, and poor prognosis. Despite its pivotal role in promoting genomic instability, cancer stemness, and metastasis, FOXM1 remains a clinically undruggable target. In this study, we identified masitinib mesylate, a small-molecule inhibitor known for its multitargeted tyrosine kinase inhibition, targeting c-Kit, PDGFRα, and PDGFRβ, as well as Lyn, which demonstrates anticancer activity in preclinical models. Masitinib mesylate emerges as a potent, novel first-in-class small-molecule inhibitor of FOXM1.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.